380 related articles for article (PubMed ID: 23256608)
1. Confounding parameters in preclinical assessment of blood-brain barrier permeation: an overview with emphasis on species differences and effect of disease states.
Deo AK; Theil FP; Nicolas JM
Mol Pharm; 2013 May; 10(5):1581-95. PubMed ID: 23256608
[TBL] [Abstract][Full Text] [Related]
2. Differential receptor-mediated drug targeting to the diseased brain.
Rip J; Schenk GJ; de Boer AG
Expert Opin Drug Deliv; 2009 Mar; 6(3):227-37. PubMed ID: 19327042
[TBL] [Abstract][Full Text] [Related]
3. Delivery of therapeutic agents to the central nervous system: the problems and the possibilities.
Begley DJ
Pharmacol Ther; 2004 Oct; 104(1):29-45. PubMed ID: 15500907
[TBL] [Abstract][Full Text] [Related]
4. Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases.
Löscher W; Potschka H
Prog Neurobiol; 2005 May; 76(1):22-76. PubMed ID: 16011870
[TBL] [Abstract][Full Text] [Related]
5. Progress in brain penetration evaluation in drug discovery and development.
Liu X; Chen C; Smith BJ
J Pharmacol Exp Ther; 2008 May; 325(2):349-56. PubMed ID: 18203948
[TBL] [Abstract][Full Text] [Related]
6. Nanotechnological advances for the delivery of CNS therapeutics.
Wong HL; Wu XY; Bendayan R
Adv Drug Deliv Rev; 2012 May; 64(7):686-700. PubMed ID: 22100125
[TBL] [Abstract][Full Text] [Related]
7. Intranasal delivery of biologics to the central nervous system.
Lochhead JJ; Thorne RG
Adv Drug Deliv Rev; 2012 May; 64(7):614-28. PubMed ID: 22119441
[TBL] [Abstract][Full Text] [Related]
8. Innovative in vitro method to predict rate and extent of drug delivery to the brain across the blood-brain barrier.
Mangas-Sanjuan V; González-Álvarez I; González-Álvarez M; Casabó VG; Bermejo M
Mol Pharm; 2013 Oct; 10(10):3822-31. PubMed ID: 23977999
[TBL] [Abstract][Full Text] [Related]
9. Addressing central nervous system (CNS) penetration in drug discovery: basics and implications of the evolving new concept.
Reichel A
Chem Biodivers; 2009 Nov; 6(11):2030-49. PubMed ID: 19937839
[TBL] [Abstract][Full Text] [Related]
10. Strategy for effective brain drug delivery.
Alam MI; Beg S; Samad A; Baboota S; Kohli K; Ali J; Ahuja A; Akbar M
Eur J Pharm Sci; 2010 Aug; 40(5):385-403. PubMed ID: 20497904
[TBL] [Abstract][Full Text] [Related]
11. Medicinal chemistry based approaches and nanotechnology-based systems to improve CNS drug targeting and delivery.
Vlieghe P; Khrestchatisky M
Med Res Rev; 2013 May; 33(3):457-516. PubMed ID: 22434495
[TBL] [Abstract][Full Text] [Related]
12. Current State and Future Perspectives in QSAR Models to Predict Blood- Brain Barrier Penetration in Central Nervous System Drug R&D.
Morales JF; Montoto SS; Fagiolino P; Ruiz ME
Mini Rev Med Chem; 2017; 17(3):247-257. PubMed ID: 27739359
[TBL] [Abstract][Full Text] [Related]
13. From naturally-occurring neurotoxic agents to CNS shuttles for drug delivery.
Soddu E; Rassu G; Giunchedi P; Sarmento B; Gavini E
Eur J Pharm Sci; 2015 Jul; 74():63-76. PubMed ID: 25892455
[TBL] [Abstract][Full Text] [Related]
14. Nano-enabled delivery systems across the blood-brain barrier.
Hwang SR; Kim K
Arch Pharm Res; 2014 Jan; 37(1):24-30. PubMed ID: 24170511
[TBL] [Abstract][Full Text] [Related]
15. Integrating in Silico and in Vitro Approaches To Predict Drug Accessibility to the Central Nervous System.
Zhang YY; Liu H; Summerfield SG; Luscombe CN; Sahi J
Mol Pharm; 2016 May; 13(5):1540-50. PubMed ID: 27015243
[TBL] [Abstract][Full Text] [Related]
16. Prediction of brain:blood unbound concentration ratios in CNS drug discovery employing in silico and in vitro model systems.
Liu H; Dong K; Zhang W; Summerfield SG; Terstappen GC
Drug Discov Today; 2018 Jul; 23(7):1357-1372. PubMed ID: 29548981
[TBL] [Abstract][Full Text] [Related]
17. Active-site concentrations of chemicals - are they a better predictor of effect than plasma/organ/tissue concentrations?
Hammarlund-Udenaes M
Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):215-20. PubMed ID: 20050843
[TBL] [Abstract][Full Text] [Related]
18. Central nervous system penetration for small molecule therapeutic agents does not increase in multiple sclerosis- and Alzheimer's disease-related animal models despite reported blood-brain barrier disruption.
Cheng Z; Zhang J; Liu H; Li Y; Zhao Y; Yang E
Drug Metab Dispos; 2010 Aug; 38(8):1355-61. PubMed ID: 20427691
[TBL] [Abstract][Full Text] [Related]
19. A physiologically based modeling strategy during preclinical CNS drug development.
Ball K; Bouzom F; Scherrmann JM; Walther B; Declèves X
Mol Pharm; 2014 Mar; 11(3):836-48. PubMed ID: 24446829
[TBL] [Abstract][Full Text] [Related]
20. Nanowired Drug Delivery Across the Blood-Brain Barrier in Central Nervous System Injury and Repair.
Sharma A; Menon P; Muresanu DF; Ozkizilcik A; Tian ZR; Lafuente JV; Sharma HS
CNS Neurol Disord Drug Targets; 2016; 15(9):1092-1117. PubMed ID: 27538949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
